Grand Pharma (00512.HK): Global innovative ophthalmic drug CBT-001 for pterygium reaches primary clinical endpoint in international multicenter Phase III clinical trial

Zhitong Finance APP News, Grand Pharma (00512.HK) announced that the international multicenter Phase III clinical trial of the Group's globally innovative ophthalmic drug CBT-001 (GPN00153) for the treatment of pterygium has recently reached its primary clinical endpoint. Compared with the placebo control group in terms of conjunctival hyperemia at Month 3 and pterygium lesion length at Month 12, both doses of CBT-001 demonstrated highly statistically significant improvements. This clinical result marks the first time a drug has demonstrated a disease-modifying therapeutic effect on pterygium through statistically significant improvement in hyperemia and lesion size. Other analyses are ongoing.